MedPath

Coffee Roasting and Glucose Tolerance

Not Applicable
Completed
Conditions
Oral Glucose Tolerance
Registration Number
NCT02417519
Lead Sponsor
University of Copenhagen
Brief Summary

Chlorogenic acid (CGA) in coffee may lower the postprandial glucose response. CGA is destroyed by dark roasting. In a controlled crossover trial, 11 healthy fasted volunteers consumed 300 mL of either light (LIR) or dark (DAR) roasted coffee, or water, followed 30 min later by a 75-g oral glucose tolerance test (OGTT). Plasma glukose and insulin, appetite, and plasma and urine metabolic profiles will be analysed. The primary aim is to investigate whether roasting affects the postprandial glucose area under the curve (AUC).

Detailed Description

Epidemiologic evidence suggests that coffee consumption is associated with a lower risk of type 2 diabetes. Coffee contains caffeine and several other components that may modulate glucose regulation. The chlorogenic acids (CGA) in coffee have been indicated as constituents that may help to normalize the acute glucose response after a carbohydrate challenge. The aim of this study was to investigate whether two coffee beverages that differ in CGA content due to different roasting degrees will affect glucose regulation differently.

In a controlled crossover trial, 11 healthy fasted volunteers consumed 300 mL of either light roasted (LIR) or dark roasted (DAR) coffee, or water, followed 30 min later by a 75-g oral glucose tolerance test (OGTT). Blood samples were drawn at baseline, 30, 60 and 120 min. Differences in glucose and insulin responses and insulin sensitivity index (ISI) were analyzed. The CGA and caffeine contents in the coffees were analyzed using UPLC-MS/MS.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
11
Inclusion Criteria

Body mass index (BMI) of 18.0-30.0 kg/m2 and with no known diseases

Exclusion Criteria
  • systemic infections,
  • psychiatric or metabolic disorders,
  • known food allergies or intolerances related to the products used in the study (e.g. dairy or gluten),
  • ongoing or former drug abuse,
  • high intake of alcohol (defined as a weekly intake of >7 units for women and > 14 units for men),
  • pregnancy or ongoing planning of pregnancy,
  • vegetarianism or veganism,
  • participation in other scientific studies during the study period, and
  • blood donation during - or in the month leading up to - the study period

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
Plasma glucose Area Under the Curve (Glucose AUC)0-120 min

The area under the plasma glucose concentration curve was calculated from 0-120min after 75g glucose was ingested.

Secondary Outcome Measures
NameTimeMethod
Plasma glucose concentrations30, 60 and120 min

changes in the glucose concentration determined by a mixed model analysis and subsequently at each time point with time 0 as a co-variate.

Serum Insulin Area Under the Curve0-120 min

Area under the curve (AUC) for serum insulin

ISI(0-120)0-120min

Matsuda's Insulin sensitivity index

Metabolic profile in plasma0-24 hours

Metabolic profile of plasma measured in all samples collected before the meal and postprandially from 0-120 min as well as in samples collected up to 24 hrs later.

Serum insulin concentrations30, 60 and120 min

changes in the insulin concentration determined by a mixed model analysis and subsequently at each time point with time 0 as a co-variate.

Metabolic profile in urine0-24 hours

Metabolic profile of urine samples measured in all samples collected before the meal and postprandially from 0-120 min 120-240min as well as in samples collected up to 24 hrs later.

Trial Locations

Locations (1)

Department of Nutrition, Exercise and Sports, University of Copenhagen

🇩🇰

Frederiksberg, Denmark

Department of Nutrition, Exercise and Sports, University of Copenhagen
🇩🇰Frederiksberg, Denmark

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.